Possible explanations for this disparity include differences in the methods used to assess myocardial glucose uptake [differences in glucose and insulin infusion protocols, i.e., supraphysiological insulinization (200 mU × min−1 × m2 insulin clamp) after an overnight insulin infusion in T2DM], and the population analyzed (T2DM with ischemic heart failure vs. individuals without cardiovascular disease or heart failure in our study). The gene discussed is INS; the disease is cardiovascular disorder.